Thrombolysis by chemically modified coagulation factor Xa

Essentials Factor Xa (FXa) acquires cleavage‐mediated tissue plasminogen activator (tPA) cofactor activity. Recombinant (r) tPA is the predominant thrombolytic drug, but it may cause systemic side effects. Chemically modified, non‐enzymatic FXa was produced (Xai‐K), which rapidly lysed thrombi in mi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2016-09, Vol.14 (9), p.1844-1854
Hauptverfasser:	Pryzdial, E. L. G., Meixner, S. C., Talbot, K., Eltringham‐Smith, L. J., Baylis, J. R., Lee, F. M. H., Kastrup, C. J., Sheffield, W. P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticoagulants - chemistry factor Xa Factor Xa - administration & dosage Factor Xa - analogs & derivatives Female Fibrinolysis Hemostasis Humans Liver - metabolism Mice Patient Safety Phospholipids - chemistry plasmin Plasminogen - chemistry Recombinant Proteins - administration & dosage Recombinant Proteins - chemistry therapeutic thrombolysis Thrombelastography Thrombolytic Therapy Thrombosis - therapy tissue plasminogen activator Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - metabolism Treatment Outcome Ultrasonography, Doppler
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!